PDCD1 and neoplasm: A second-generation variant of gavo-cel called TC-510 was subsequently developed by incorporating a costimulatory programmed cell death protein 1 (PD-1):CD28 switch receptor to enhance signaling, promote proliferation and reduce T-cell exhaustion, and demonstrated tumor regression but apparent target-related toxicity in a Phase 1/2 clinical trial in MSLN-expressing solid tumors (NCT05451849) (13).